Omidenepag is a selective, non-prostanoid prostaglandin E2 (EP2) receptor agonist and is the active form generated from the prodrug omidenepag isopropyl. Omidenepag is primarily associated with ophthalmic pharmaceutical research and the development of therapies for elevated intraocular pressure, including glaucoma and ocular hypertension. It is identified by CAS Number 1187451-41-7, with the molecular formula C23H22N6O4S and molecular weight approximately 478.52 g/mol. PubChem identifies Omidenepag as a prostaglandin E2 receptor agonist and reports CAS 1187451-41-7.
Omidenepag is chemically different from Omidenepag Isopropyl, the prodrug used in ophthalmic formulations. Omidenepag Isopropyl has CAS Number 1187451-19-9, molecular formula C26H28N6O4S, and molecular weight 520.61 g/mol. This distinction is important when preparing API specifications, product catalogs, technical documents and procurement records.
Omidenepag is a relatively complex heterocyclic small molecule containing pyridine, pyrazole, sulfonamide and glycine-derived structural features. Its IUPAC name is 2-[[6-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]-2-pyridinyl]amino]acetic acid. PubChem reports the canonical molecular formula as C23H22N6O4S and molecular weight as 478.5 g/mol.
Omidenepag is achiral, with no defined stereocenters reported by the NCATS Inxight Drugs database. This is relevant when establishing API identity and analytical specifications because stereochemical purity testing applicable to chiral APIs is not directly applicable in the same manner to this compound.
Omidenepag is a selective agonist of the prostaglandin EP2 receptor. Unlike traditional prostanoid FP-receptor agonists, Omidenepag belongs to a non-prostanoid EP2 agonist class. Research data describe strong EP2 receptor activity, with an EC50 reported around 1.1 nM and binding affinity around 10 nM for the human EP2 receptor in the cited experimental systems.
Activation of EP2 receptors in ocular tissues promotes aqueous-humor outflow, contributing to reduction of intraocular pressure. Omidenepag is therefore relevant to pharmaceutical research involving glaucoma, ocular hypertension and intraocular-pressure management. The active compound is generated from Omidenepag Isopropyl, which functions as a prodrug for ophthalmic administration.
A major technical point for API buyers is the distinction between Omidenepag and Omidenepag Isopropyl.
This distinction should be maintained throughout product titles, CAS records, certificates, specifications and SEO content to avoid attracting searches for the wrong chemical substance.
Omidenepag is relevant to pharmaceutical research and development associated with ocular hypotensive therapy. Its selective EP2 receptor pharmacology makes it an important compound for ophthalmic drug development and research into alternative mechanisms for lowering intraocular pressure.
Potential pharmaceutical and analytical applications include:
The marketed ophthalmic product Omlonti contains omidenepag isopropyl, rather than the free Omidenepag molecule. The FDA-approved product is an ophthalmic solution containing 0.02 mg/mL omidenepag isopropyl, corresponding to 0.002% w/v.
Quality evaluation of Omidenepag should include appropriate identity and purity testing. Available analytical references report ≥98% HPLC purity for Omidenepag research material, while another current analytical listing reports 99.86% purity. These values demonstrate commercially available high-purity material but should not be presented as a universal pharmacopoeial API release specification.
Recommended analytical characterization can include HPLC for purity and related substances, LC-MS or mass spectrometry for molecular confirmation, IR spectroscopy for structural identification and NMR for detailed structural characterization. Because Omidenepag is a relatively specialized pharmaceutical compound, commercial API acceptance limits should be established against the applicable validated specification rather than generic limits.
Omidenepag is described as a solid powder, with commercial research references identifying the material as white to off-white. Cayman Chemical lists Omidenepag free acid as a solid with a formula weight of 478.5 g/mol and purity of ≥98%. It reports slight solubility in acetonitrile and sparing solubility in DMSO.
Other analytical references report DMSO solubility up to 250 mg/mL under specified laboratory conditions, although such values are method- and preparation-dependent and should not be treated as an aqueous API solubility specification.
A reliable universal experimental melting point for Omidenepag was not identified in the authoritative sources reviewed. Chemical safety documentation also reports the melting/freezing point as unavailable. Therefore, a specific melting-point value should not be invented for the CMS.
Omidenepag Bulk API documentation should clearly specify CAS 1187451-41-7 and distinguish the free acid from Omidenepag Isopropyl CAS 1187451-19-9. This is particularly important because the two compounds have different molecular formulas, molecular weights and pharmaceutical roles.
For technical procurement and quality evaluation, API documentation should include the identity, assay/purity, related substances, residual solvents, water content, physical characteristics, analytical methods and storage conditions applicable to the actual material supplied.
Available research references recommend cold storage for Omidenepag solid material, including −20°C for long-term storage. However, commercial pharmaceutical API storage should follow the manufacturer's validated stability data, packaging qualification and approved storage conditions rather than automatically adopting research-reagent recommendations.
An Omidenepag API Manufacturer in India product page should emphasize accurate chemical identification, pharmaceutical-quality analytical controls and the distinction between Omidenepag and its isopropyl prodrug. Important searchable identifiers include Omidenepag API, Omidenepag API Manufacturer, Omidenepag API Manufacturer India, Omidenepag Pharmaceutical API, Omidenepag Bulk API, Omidenepag CAS Number, UR-7276 API, and CAS 1187451-41-7.
For SEO and technical accuracy, the product should be described as Omidenepag free acid / active form, while Omidenepag Isopropyl should be treated as a separate product page because it has its own CAS number and molecular identity.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | NLT 98.0% by HPLC |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.2% |
| Heavy Metals | NMT 10 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | NMT 0.10% |
| Total Impurities | NMT 0.50% |
| Water Content | NMT 1.0% |